Evercore ISI lowered the firm’s price target on Savara (SVRA) to $2 from $3 and keeps an In Line rating on the shares. Chemistry, Manufacturing, and Controls “plagued” the BLA for Molbreevi in autoimmune pulmonary alveolar proteinosis, as the firm expected, the analyst tells investors. The firm, which expects Savara could be ready to refile the BLA in Q4, has pushed out launch expectations to January 2027, while maintaining its view of 60% probability of approval pending additional details, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara price target lowered to $8 from $9 at Guggenheim
- Savara price target lowered to $7 from $8 at Wells Fargo
- U.S. extends EU tariff deadline, Salesforce to acquire Informatica: Morning Buzz
- Savara Faces FDA Setback for MOLBREEVI Application
- Savara receives RTF letter from FDA for Molbreevi BLA